About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Drug Utilization Reviews and Medication Therapy Management Programs Under the Gun
Medicare wants to improve its drug program’s effectiveness, reduce costs, and
increase its oversight of formulary policies and prescribing, especially for opioids.
Health Care and Law
Enhancing Pharmacy Practice and Limiting Risk
P&T committee members, many of whom are not pharmacists, must be able to understand their organization’s P&Ps in order to minimize patient injury and avoid legal land mines.
James O’Donnell, PharmD, MS; and F. Randy Vogenberg, RPh, PhD
Almost 10 million people in the U.S., many of them elderly, have various forms of this troubling condition. The types and causes of, risk factors for, and physiology of urinary incontinence, as well as conservative and pharmacological treatments, are discussed.
George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD
Topics include interferon-free therapies, pegylated interferon lambda-1a, and
boceprevir (Victrelis) for the treatment of hepatitis C virus infection.
Sessions included therapies for psoriasis, acne, nail fungus, and superficial skin cancers.
Peter Sonnenreich, MA
Overcoming Bystander Apathy
Eliminating bystander apathy requires active participation.
Matthew Grissinger, RPh, FASCP
Differentiating ‘Scientific Exchange’ From ‘Promotion’ Is Complicated
Will the FDA ease restrictions on disseminating unsolicited requests for off-label
FDA approvals, drug indications, and updates
Florbetapir F18 (Amyvid) dye for detecting plaques in Alzheimer’s disease; avanafil (Stendra) for erectile dysfunction; and peginesatide injection (Omontys) for anemia in patients with chronic kidney disease
Marvin M. Goldenberg, PhD, RPh, MS